A new article published in the journal Nature is reporting promising results from a landmark Phase 1 human trial testing a novel vaccine designed to help a patient’s immune system better target brain tumors. The data suggests the experimental vaccine is safe and stimulates a significant immune response that slows tumor progression. A larger Phase 2 trial is currently being planned.
A novel cancer vaccine is moving to Phase 1 human trials in the United States after promising results from animal studies showed encouraging efficacy and a robust safety profile. A new study describes the vaccine as producing complete responses in 90 percent of animals when combined with a second immunotherapy drug.